ID CLB HC.PH.BIO.CLB
Develops drugs, biologics or cell and gene therapies with no approved product on the market (no revenue, or milestones only); such a developer is here, not in contract research.
Sector, group and industry above this class, as placed in the current release. The sector and the industry link to their companies.
Companies whose primary class this is. The sector and industry pages and the screener count them the same way.
| Company | Ticker | Country | Market cap | Filings |
|---|---|---|---|---|
| Opus Genetics, Inc. | IRD | United States of America | $309.50M | 1,065 |
| PALISADE BIO, INC. | PALI | United States of America | $302.38M | 1,225 |
| Neurogene Inc. | NGNE | United States of America | $413.06M | 764 |
| Greenwich LifeSciences, Inc. | GLSI | United States of America | $324.54M | 278 |
| Vicore Pharma Holding | VICO | Sweden | $296.46M | 277 |
| Surrozen, Inc. | SRZN | United States of America | $249.86M | 508 |
| CRESCENT BIOPHARMA, INC. | CBIO | United States of America | $496.35M | 682 |
| Rezolute, Inc. | RZLT | United States of America | $291.88M | 760 |
| ANAVEX LIFE SCIENCES CORP. | AVXL | United States of America | $287.28M | 671 |
| Protara Therapeutics, Inc. | TARA | United States of America | $281.78M | 820 |
| AC Immune SA | ACIU | Switzerland | $241.71M | 318 |
| C4 Therapeutics, Inc. | CCCC | United States of America | $406.33M | 571 |
| SAB Biotherapeutics, Inc. | SABS | United States of America | $295.53M | 444 |
| Enlivex Therapeutics Ltd. | ENLV | Israel | $207.52M | 488 |
| Foghorn Therapeutics Inc. | FHTX | United States of America | $243.08M | 369 |
| Cabaletta Bio, Inc. | CABA | United States of America | $257.03M | 478 |
| TENAX THERAPEUTICS, INC. | TENX | United States of America | $284.61M | 1,000 |
| Editas Medicine, Inc. | EDIT | United States of America | $255.45M | 797 |
| Context Therapeutics Inc. | CNTX | United States of America | $249.91M | 315 |
| ALX ONCOLOGY HOLDINGS INC | ALXO | United States of America | $285.95M | 477 |
| TriSalus Life Sciences, Inc. | TLSI | United States of America | $198.99M | 512 |
| COMPUGEN LTD | CGEN | United States of America | $191.06M | 599 |
| ABEONA THERAPEUTICS INC. | ABEO | United States of America | $402.39M | 1,283 |
| Eledon Pharmaceuticals, Inc. | ELDN | United States of America | $277.88M | 634 |
| Camp4 Therapeutics Corp | CAMP | United States of America | $243.50M | 203 |
| Circio Holding ASA | CRNA | Norway | $210.59M | 282 |
| Alector, Inc. | ALEC | United States of America | $166.54M | 652 |
| Minerva Neurosciences, Inc. | NERV | United States of America | $196.14M | 630 |
| Sensorion | ALSEN | France | $139.78M | 602 |
| Voyager Therapeutics, Inc. | VYGR | United States of America | $237.80M | 687 |
| Transgene | TNG | France | $237.08M | 912 |
| Silence Therapeutics plc | SLN | United Kingdom | $518.64M | 683 |
| Saniona | SANION | Sweden | $197.05M | 453 |
| Inhibikase Therapeutics, Inc. | IKT | United States of America | $215.21M | 376 |
| BioVersys AG | BIOV | Switzerland | $219.63M | 174 |
| Avidity Biosciences, Inc. | RNA | United States of America | $201.68M | 539 |
| KALA BIO, Inc. | KALA | United States of America | $38.30M | 677 |
| Compugen Ltd. | CGEN | Israel | $216.33M | 1,383 |
| Enlivex Ltd. | ENLV | United States of America | $195.32M | 449 |
| Nuvectis Pharma, Inc. | NVCT | United States of America | $253.05M | 280 |
| Elicio Therapeutics, Inc. | ELTX | United States of America | $195.92M | 386 |
| Prelude Therapeutics Inc | PRLD | United States of America | $193.00M | 406 |
| Milestone Pharmaceuticals Inc. | MIST | United States of America | $153.13M | 644 |
| Adagene Inc. | ADAG | Cayman Islands | $188.05M | 204 |
| Canton Strategic Holdings, Inc. | CNTN | United States of America | $187.37M | 305 |
| Jyong Biotech Ltd. | MENS | United States of America | $153.58M | 73 |
| MACROGENICS INC | MGNX | United States of America | $248.53M | 975 |
| Caribou Biosciences, Inc. | CRBU | United States of America | $184.13M | 344 |
| Artiva Biotherapeutics, Inc. | ARTV | United States of America | $481.99M | 243 |
| Turn Therapeutics Inc. | TTRX | United States of America | $178.73M | 80 |
Other names for this activity, and where neighboring activities go instead.
preclinicaldrug developer
Research-led company whose approved medicines, which it discovered, are in one or two therapeutic areas; it moves to Branded Prescription Drugs only after two consecutive annual reports with approved products in three or more.
https://financialfilings.com/oics/CLB/
This page is keyed by the class ID CLB. IDs are assigned in v0.3 and freeze at v1.0; from then on an ID is never renamed or reused, and if the class moves in the tree, its ID and this URL stay the same.
Sign in or create a free account - no password needed.
By continuing, you agree to our Terms and Privacy Policy.